MEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ — Imagine. A nick of the skin, a flash of cold and 25 minutes on an exam table. For thousands of women, this may soon replace surgery as a treatment for breast cancer.
Cryoablation, using extreme cold to destroy diseased cells, is potentially the first ever procedure to treat breast cancer tumors without the trauma of surgery. Following numerous limited studies, a growing number of women are now being treated with the technique as part of a groundbreaking clinical trial involving leading breast cancer specialists across the country. Utilizing IceCure Medical’s innovative IceSense3™ cryoablation system, the multi-center trial is examining cryoablation of certain types of breast cancer. Potentially, it will usher in a new and gentler pathway for the treatment of a disease that affects one in every eight women annually. read more
New Study Shows Wearable Ventilation Technology Significantly Improved Outcomes in Patients with Moderate to Severe Respiratory Disease
MONTREAL, Oct. 26, 2015 /PRNewswire/ — New data were presented today demonstrating that use of a wearable ventilator system in COPD patients with chronic respiratory insufficiency is associated with significant improvement in healthcare utilization and overall respiratory health status.
Study findings were released in a session titled “Health Care Utilization and Respiratory Health Status in Patients with Chronic Respiratory Insufficiency Following Addition of a Portable Non-Invasive Ventilator to the Treatment Regimen” at the annual American College of Chest Physicians (CHEST 2015) meeting taking place from October 24-28 in Montreal.
Entacapone: Drug Safety Communication – FDA Review Found No Increased Cardiovascular Risks
An FDA safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson’s disease. As a result, recommendations for using Comtan (entacapone) and Stalevo (a combination of entacapone, carbidopa, and levodopa) will remain the same in the drug labels. read more
Allergan Acquires Rights To Ironwood’s CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
Signals Allergan’s Commitment to Offering Innovative GI Therapies for Patients and Physicians Worldwide —
DUBLIN and CAMBRIDGE, Mass., Oct. 27, 2015 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that Allergan has acquired rights to CONSTELLA® (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to LINZESS® (linaclotide) in Mexico from Almir read more
Baxter Reports Strong Third Quarter Financial Results Exceeding Previously Issued Guidance
Company Well-Positioned to Deliver Solid, Sustained Growth as Leading Medical Products Enterprise; Momentum Continues with Clear Focus on Expanding Margins and Value Creation read more
Orexo Settles Abstral® US Patent Litigation with Actavis
Orexo AB (publ) today announced that it has entered into a settlement and license agreement with Actavis Laboratories FL, Inc. (“Actavis”) to settle the patent litigation regarding Abstral® in the U.S.
The agreement settles the patent infringement litigation commenced early this year by Orexo following Actavis’ filing of an Abbreviated New Drug Application (“ANDA”) seeking approval to market generic versions of Abstral® (fentanyl) sublingual tablets in the U.S. prior to the expiration of Orexo’s patents listed in FDA’s Orange Book for Abstral®.
The agreement allows Actavis to enter the market in June 2018, or earlier under certain conditions. Orexo’s patents listed in FDA’s Orange Book for Abstral® expire in September 2019.
NeuroMetrix Announces Distribution Agreement With Prism Health Care Services
BOSTON–(BUSINESS WIRE)–NeuroMetrix, Inc. (NASDAQ:NURO) and Prism Health Care Services, Inc., an affiliate of The Alden Network, today announced an agreement under which Prism will be the exclusive distributor of Quell® wearable pain relief technology in Illinois and Wisconsin for patients in assisted and independent living centers. Prism is also authorized to distribute Quell to other health care centers in the region. read more
GSK’s candidate Shingles Vaccine Containing Agenus’ QS-21 Stimulon® Demonstrates 90% Efficacy against Shingles and 89% Efficacy against Post-Herpetic Neuralgia in Adults aged 70 Years and Older
LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancer and other diseases, announced today that GlaxoSmithKline’s plc (LSE/NYSE:GSK) second pivotal Phase III efficacy study of its shingles vaccine candidate containing Agenus’ QS-21 Stimulon® adjuvant demonstrated 90% overall efficacy against shingles compared to placebo. In this trial known as ZOE-70 (Zoster efficacy in adults aged 70 years and over) the vaccine candidate HZ/su was studied in adults aged 70 years and older.i These results are consistent with the first pivotal Phase III study, ZOE-50, which demonstrated an efficacy of 97.2% in adults age 50 years and older. In ZOE-50, 53% of the subjects were over 60, and almost 24% were over 70 years of age.ii
Teleflex Introduces Comfort Flo® Plus Cannula for Heated High Flow Nasal Cannula Therapy
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, announced today the launch of the Comfort Flo® Plus High Flow Nasal Cannula. This new product addition expands the company’s portfolio of Heated High Flow Nasal Cannula Therapy (HFNCT) solutions and is designed to enhance patient comfort. read more